Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica Rubino, Frank L. Greenway, Usman Khalid, et al.
JAMA (2022) Vol. 327, Iss. 2, pp. 138-138
Open Access | Times Cited: 575

Showing 1-25 of 575 citing articles:

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1498
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 542
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 419
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 405
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 249
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 231
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
Mohit Sodhi, Ramin Rezaeianzadeh, Abbas Kezouh, et al.
JAMA (2023) Vol. 330, Iss. 18, pp. 1795-1795
Open Access | Times Cited: 208
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 205
Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
Mojca Jensterle, Manfredi Rizzo, Martin Haluzı́k, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2452-2467
Open Access | Times Cited: 128
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
Wissam Ghusn, Alan De la Rosa, Daniel Sacoto, et al.
JAMA Network Open (2022) Vol. 5, Iss. 9, pp. e2231982-e2231982
Open Access | Times Cited: 128
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Eduardo Grunvald, Raj Shah, Rubén Hernáez, et al.
Gastroenterology (2022) Vol. 163, Iss. 5, pp. 1198-1225
Open Access | Times Cited: 126
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 124
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Jingyue Wang, Quanwei Wang, Xinyu Yang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 120
Semaglutide for the treatment of overweight and obesity: A review
Natasha C. Bergmann, Melanie J. Davies, Ildiko Lingvay, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 1, pp. 18-35
Open Access | Times Cited: 106
Excess body weight: Novel insights into its roles in obesity comorbidities
Xiang Zhang, Suki Ha, Harry Cheuk-Hay Lau, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 16-27
Open Access | Times Cited: 103
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 103
New insights into the treatment of obesity
Matthias Blüher, Mohini Aras, Louis J. Aronne, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2058-2072
Closed Access | Times Cited: 85
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
Anders Boisen Jensen, Frida Renström, Stefan Aczél, et al.
Obesity Surgery (2023) Vol. 33, Iss. 4, pp. 1017-1025
Open Access | Times Cited: 84
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 78
Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)
John P. Kirwan, Anita P. Courcoulas, David E. Cummings, et al.
Diabetes Care (2022) Vol. 45, Iss. 7, pp. 1574-1583
Open Access | Times Cited: 76
Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials
Omar S. Alkhezi, Abdullah A. Alahmed, Osamah M. Alfayez, et al.
Obesity Reviews (2022) Vol. 24, Iss. 3
Closed Access | Times Cited: 76
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 73
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Ildiko Lingvay, Kirstine Brown‐Frandsen, Helen M. Colhoun, et al.
Obesity (2022) Vol. 31, Iss. 1, pp. 111-122
Open Access | Times Cited: 72
Obesity in South and Southeast Asia—A new consensus on care and management
Kwang Wei Tham, Rohana Abdul Ghani, C. Sioksoan, et al.
Obesity Reviews (2022) Vol. 24, Iss. 2
Open Access | Times Cited: 71
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery
Jessica Mok, Mariam O. Adeleke, Adrian Brown, et al.
JAMA Surgery (2023) Vol. 158, Iss. 10, pp. 1003-1003
Open Access | Times Cited: 71
Page 1 - Next Page

Scroll to top